Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for IOL Chemicals And Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
NSE:IOLCP'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0 Med: 0.41 Max: 4.56
Current: 0.49
During the past 13 years, the highest Debt-to-EBITDA Ratio of IOL Chemicals And Pharmaceuticals was 4.56. The lowest was 0.00. And the median was 0.41.
NSE:IOLCP's Debt-to-EBITDA is ranked better than 73.33% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs NSE:IOLCP: 0.49
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
IOL Chemicals And Pharmaceuticals Debt-to-EBITDA Related Terms
IOL Chemicals And Pharmaceuticals Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IOL Chemicals And Pharmaceuticals Debt-to-EBITDA Chart
For the Drug Manufacturers - Specialty & Generic subindustry, IOL Chemicals And Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IOL Chemicals And Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, IOL Chemicals And Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IOL Chemicals And Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
IOL Chemicals And Pharmaceuticals (NSE:IOLCP) has a Debt-to-EBITDA of 0.36 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on IOL Chemicals And Pharmaceuticals. This is 12% below median its historical median of 0.41. According to the industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #184 out of 690 companies in the Drug Manufacturers industry, placing it in the top 26.7%.
Is IOL Chemicals And Pharmaceuticals' Debt-to-EBITDA too high?
IOL Chemicals And Pharmaceuticals' current Debt-to-EBITDA of 0.36 is 12% below median its 10-year median of 0.41. The Drug Manufacturers industry median Debt-to-EBITDA is 1.68. IOL Chemicals And Pharmaceuticals' value of 0.36 is 78.6% below this industry median. Based on the distribution chart, IOL Chemicals And Pharmaceuticals ranks #184 out of 690 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, IOL Chemicals And Pharmaceuticals has a GF Score™ of 64/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IOL Chemicals And Pharmaceuticals' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, IOL Chemicals And Pharmaceuticals ranks #184 out of 690 companies for Debt-to-EBITDA. This puts IOL Chemicals And Pharmaceuticals in the upper half of its industry. The industry median Debt-to-EBITDA is 1.68. IOL Chemicals And Pharmaceuticals' value of 0.36 is 78.6% below this benchmark. While the company's 10-year median is 0.41 vs. the industry median of 1.68, IOL Chemicals And Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IOL Chemicals And Pharmaceuticals's current Debt-to-EBITDA of 0.36 is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on IOL Chemicals And Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IOL Chemicals And Pharmaceuticals's current Debt-to-EBITDA is 0.36, which is 12% below median its own 10-year median of 0.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IOL Chemicals And Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals (NSE:IOLCP) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹94.10, compared to a current price of ₹148.33 — trading 57.6% above its estimated fair value. The current Debt-to-EBITDA is 0.36, which is 12% below median its 10-year median of 0.41 and 78.6% below the Drug Manufacturers industry median of 1.68. IOL Chemicals And Pharmaceuticals' overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For IOL Chemicals And Pharmaceuticals (NSE:IOLCP), the current Debt-to-EBITDA is 0.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IOL Chemicals And Pharmaceuticals (NSE:IOLCP) Overvalued in 2026?
Based on GuruFocus' analysis, IOL Chemicals And Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹148.33 is trading 57.6% above its estimated GF Value™ of ₹94.10.
GuruFocus considers IOL Chemicals And Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:IOLCP:
Debt-to-EBITDA: 0.36 (12% below median its 10-year median of 0.41)
GF Value™: ₹94.10 vs. price of ₹148.33 (57.6% above fair value)
Industry Position: 78.6% below the Drug Manufacturers median (#184 of 690)
No single metric tells the full story. See the NSE:IOLCP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IOL Chemicals And Pharmaceuticals Business Description
IOL Chemicals And Pharmaceuticals Ltd is an India-based pharmaceutical company. The primary activity of the group is the manufacturing and sale of drugs and organic chemicals. The business activity is functioned through the Chemicals and Pharmaceutical segments. The Chemicals segment produces and sells chemicals such as Ethyl Acetate, Acetic Anhydride, Acetyl Chloride, Mono Chloro Acetic Acid, and Iso Butyl benzene, whereas the Pharmaceutical segment produces and sells various active pharmaceutical ingredients such as Ibuprofen, Metformin, Fenofibrate, Lamotrigine, and others. It derives prime revenue from the Pharmaceutical segment. Geographically, the group's products are sold in both the Indian and international markets.
64GF Score
Get the complete analysis for NSE:IOLCP
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:IOLCP has been successfully added to your 
